TITLE

Healthy Biotech Protects: EPS With 20-Year Issue

AUTHOR(S)
Santini, Laura
PUB. DATE
July 2003
SOURCE
Investment Dealers' Digest;7/21/2003, Vol. 69 Issue 29, p35
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on biotechnology company MedImmune Inc.'s convertible bond offering, that carried a 20-year maturity and a contingent conversion feature. Description of contingent conversion features; Expected percentage growth in sales of MedImmune; Terms of the offering; Conversion price offered by MedImmune.
ACCESSION #
10376449

 

Related Articles

  • INVESTMENT BANKING DATABASE: HEALTHCARE.  // Investment Dealers' Digest;4/19/2004, Vol. 70 Issue 16, p22 

    Presents an overview of investment banking in the healthcare industry in the U.S. in 2004. Healthcare underwriting; Stocks; Taxable municipal funds; Convertibles.

  • COMPANY SPOTLIGHT -- MedImmune.  // PharmaWatch: Biotechnology;Feb2007, Vol. 6 Issue 2, p20 

    The article features MedImmune Inc., a biotechnology company that focuses on the areas of infectious disease, oncology and immunology. The company has marketed four products including Synagis, Flumist, Ethyol and Cytogam. Moreover , the company has operated facilities in the U.S. and Europe in...

  • Move over, Net! Here come the biotech converts. Hahn, Avital Louria // Investment Dealers' Digest;02/28/2000, Vol. 66 Issue 9, p12 

    Reports popularity of biotechnology convertible bonds as of February 2000. Statistics comparing performance of Internet and biotechnology convertible bonds; Role of Human Genome Sciences Inc. in starting the trend; Increase in prices of convertible bonds.

  • Soaring convert market falls to earth with a thud. Hahn, Avital Louria // Investment Dealers' Digest;3/27/2000, Vol. 66 Issue 13, p5 

    Reports on the drop on convert issuance in the convertible deal market in the United States in March 2000 following a turnaround experienced in February 2000. Single deal for the week; Reasons for the decline; Impact of President Bill Clinton's remarks on genomic research on the stagnancy of...

  • More biotechs gamble on convertibles. Mitchell, Pete // Nature Biotechnology;Oct2001, Vol. 19 Issue 10, p894 

    Reports that biotechnology companies are turning to convertible issues as alternative sources of funding. Major biotechnology convertible issues/bonds trading on the U.S. market; Risk associated with convertibles; Status of the U.S. convertible market.

  • COMPANY SPOTLIGHT - MedImmune, Inc.  // PharmaWatch: Biotechnology;Aug2006, Vol. 5 Issue 8, p22 

    The article reports on the green light given by the Food and Drug Administration to Medlmmune Inc. to utilize an inverse genetics technology in making a vaccine strain for seasonal influenza. The company will apply the genetic technology to its FluMist product and next generation refrigerator....

  • INVESTMENT BANKING DATABASE: MEDIA/ENTERTAINMENT.  // Investment Dealers' Digest;4/19/2004, Vol. 70 Issue 16, p48 

    Presents an overview of investment banking and underwriting in media and entertainment in the U.S. in 2004. Common stocks; Convertible stocks; Taxable municipals; Goldman Sachs; Bear Stearns; Morgan Stanley.

  • INVESTMENT BANKING DATABASE: TECHNOLOGY.  // Investment Dealers' Digest;4/19/2004, Vol. 70 Issue 16, p54 

    Presents an overview of investment banking and underwriting in the technology market in the U.S. in 2004. Common stocks; Convertible stocks; Taxable municipals; Citigroup; JP Morgan Chase; Deutsche Bank; UBS.

  • Biotech Heats Up Converts. Appin, Rick // High Yield Report;6/23/2003, Vol. 14 Issue 25, p4 

    Reports on the recovery of the biotechnology stock prices in the U.S. Taking advantage of the convertible bond market; Offerings made by biotechnology different companies.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics